Brief: Xvivo Perfusion Q2 Adjusted EBITDA Rises To SEK 11.3 Mln
July 13 (Reuters) - Xvivo Perfusion AB XVIVO.ST :
* XVIVO PRESENTS INTERIM REPORT JANUARY-JUNE 2022
* Q2 NET SALES SEK 94.3 MILLION VERSUS SEK 59.3 MILLION YEAR
AGO
* Q2 ADJUSTED EBITDA SEK 11.3 MILLION VERSUS SEK 8.4 MILLION
YEAR
AGO
* Q2 NET PROFIT SEK 7.5 MILLION VERSUS NET LOSS SEK 8.9
MILLION
YEAR AGO
Source text for Eikon: ID:nMFNc1D4qZ
Further company coverage: XVIVO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Xvivo Perfusion AB
See all newsSweden's XVIVO Q3 revenue beat expectations on thoracic sales
Brief: Xvivo Q3 EBIT SEK 28 Million
Brief: Xvivo Receives CE Certificates For Heart Preservation Technology
Brief: XVIVO Gets FDA Approval For Additional Patient Enrollment
Sweden's XVIVO Q2 sales beat estimates, helped by thoracic segment strength